Ticker League

Operating Cash Flow for Biogen (BIIB)

As of · Reported

Metric

Latest period

$645.50M

YoY change

-23.3%

5Y CAGR

-12.2%

Peak year (2019)

$7.08B

Operating Cash Flow history chart for Biogen (BIIB) from 1989 to 2025

Latest: $2.20B

Operating Cash Flow growth chart for Biogen (BIIB) from 1989 to 2025

Latest: -23.3%

Operating Cash Flow history table for Biogen (BIIB) from 1989 to 2025

  • 2025$2.20B-23.3%
  • 2024$2.88B+85.9%
  • 2023$1.55B+11.8%
  • 2022$1.38B-62.0%
  • 2021$3.64B-13.9%
  • 2020$4.23B-40.2%
  • 2019$7.08B+14.4%
  • 2018$6.19B+36.0%
  • 2017$4.55B+0.6%
  • 2016$4.52B+21.7%
  • 2015$3.72B+26.3%
  • 2014$2.94B+25.5%
  • 2013$2.35B+24.7%
  • 2012$1.88B+8.8%
  • 2011$1.73B+6.3%
  • 2010$1.62B+51.1%
  • 2009$1.07B-31.3%
  • 2008$1.56B+53.3%
  • 2007$1.02B+21.3%
  • 2006$841.27M-5.4%
  • 2005$889.50M+22.2%
  • 2004$727.99M+232.1%
  • 2003$219.21M+22.3%
  • 2002$179.22M-43.3%
  • 2001$316.36M-13.5%
  • 2000$365.94M+34.4%
  • 1999$272.29M+62.2%
  • 1998$167.84M+71.9%
  • 1997$97.63M+109.8%
  • 1996$46.54M+392.5%
  • 1995$9.45M-72.9%
  • 1994$34.89M-26.7%
  • 1993$47.60M+10.4%
  • 1992$43.10M+630.5%
  • 1991$5.90M-44.9%
  • 1990$10.70M-242.7%
  • 1989−$7.50M—

Operating Cash Flow values are taken from Biogen's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Cash Flow at Biogen (BIIB)

Operating Cash Flow for Biogen (BIIB): headline value $645.50M · YoY -23.3%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Biogen (BIIB) most recent annual operating cash flow stands at $2.20B (2025) – declined 23.3% year-over-year.

Over 2020–2025 (5 years), Biogen operating cash flow expanded at a -12.2% compound annual rate, with a net decline across the window.

Biogen operating cash flow plunged from $7.08B in 2019 to $2.20B in 2025, a 68.9% drawdown.

$7.08B stands as the all-time-high annual operating cash flow, posted in 2019, against a low of −$7.50M during 1989.

Biogen Operating Cash Flow by Year

Biogen Operating Cash Flow 2025: $2.20B

In 2025, Biogen reported operating cash flow of $2.20B, declined 23.3% below 2024.

Biogen Operating Cash Flow 2024: $2.88B

Biogen operating cash flow in 2024 was $2.88B, surged 85.9% from 2023.

Biogen Operating Cash Flow 2023: $1.55B

2023's operating cash flow for Biogen came in at $1.55B, grew 11.8% from 2022.

Biogen Operating Cash Flow 2022: $1.38B

Biogen posted operating cash flow of $1.38B in 2022, plunged 62.0% below 2021.

Biogen Operating Cash Flow 2021: $3.64B

Biogen operating cash flow in 2021 was $3.64B.

See more financial history for Biogen (BIIB).

Sector peers by Operating Cash Flow

Healthcare peers of Biogen (BIIB), ranked by their latest operating cash flow

Frequently asked questions

Biogen (BIIB) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return

No dividends paid by this company.